Why are Hectoral and Zemplar administered to patients?

Hectoral and Zemplar are medications that are primarily prescribed to patients with chronic kidney disease who are experiencing secondary hyperparathyroidism, a condition that can occur when the kidneys struggle to maintain proper levels of calcium and phosphorus in the blood. These medications are active forms of Vitamin D, which are crucial for patient management in renal failure.

In such cases, patients often have difficulty converting standard Vitamin D into its active form because their kidneys are not functioning properly. By administering Hectoral and Zemplar, healthcare providers can directly supplement the active form of Vitamin D, which helps to regulate calcium levels and suppress parathyroid hormone secretion. This administration is essential in preventing complications associated with mineral metabolism, thereby improving bone health and overall patient outcomes.

Thus, the use of these medications is directly linked to addressing the deficiency in Vitamin D conversion in individuals with compromised kidney function.